ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Development of a Non-Invasive Prediction Model for MASLD Using Routine Clinical and Biochemical Markers: A Retrospective Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, is a leading chronic liver condition associated with obesity and metabolic syndrome. Practical non-invasive models based on commonly available clinical and biochemical indicators may support risk stratification in health-check settings. Methods: This retrospective observational study included 8181 adults who underwent routine health examinations at the Health Examination Center of The First Hospital of Jiaxing from January 2024 to November 2024, including 4814 participants without MASLD and 3367 participants with ultrasound-reported hepatic steatosis after exclusion of secondary causes. Baseline comparisons, univariable logistic regression, multivariable logistic regression, Spearman correlation analysis, receiver operating characteristic (ROC) analysis, multicollinearity assessment, calibration assessment, and five-fold cross-validation were performed. Results: In the final model, older age, overweight, obesity, higher triglycerides, higher alanine aminotransferase, and higher uric acid were associated with higher odds of MASLD, whereas vitamin K was inversely associated with MASLD after adjustment. The final equation was logit(P) = -6.5363 + 0.0387 × age + 1.3838 × overweight + 2.6166 × obesity - 1.6016 × underweight + 1.0122 × triglycerides + 0.0267 × ALT + 0.0048 × uric acid - 0.1784 × vitamin K. The model achieved an AUC of 0.894 (95% CI 0.888-0.901). At the Youden-index cutoff of 0.402, sensitivity was 0.819 and specificity was 0.811. Five-fold cross-validation yielded a mean AUC of 0.894. Conclusion: A prediction model based on routine clinical and biochemical markers showed good discrimination for MASLD status in a single-center health examination cohort. Vitamin K was identified as an inversely associated exploratory marker, but this association should be interpreted cautiously and requires prospective and external validation before clinical or interventional conclusions can be drawn.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.